Abstract:Liver fibrosis is a key process in the progression of chronic liver disease to cirrhosis. Currently, early diagnosis and precise staging of liver fibrosis remain great challenges. Extracellular matrix (ECM) molecules expressed specifically during liver fibrosis are ideal targets for bioimaging and detection of liver fibrosis. Here, we report that fluorescent probes based on a nucleic acid aptamer (ZY-1) targeting cellular fibronectin (cFN), a critical ECM molecule significantly accumulating during liver fibrosis, are promising bioimaging agents for the staging of liver fibrosis. In the work, the outstanding binding affinity of ZY-1 to cFN was validated through an in vitro model of human-derived hepatic stellate cells (HSCs). Subsequently, we constructed different ZY-1-based fluorescent probes and explored the real-time imaging performance of these fluorescent probes in CCl 4 -induced mouse models of different liver fibrosis stages. The ZY-1-based fluorescent probes, for the first time, effectively identified and distinguished early-stage liver fibrosis (stage 3 of Ishak 6) from advanced liver fibrosis (stage 5 of Ishak 6). The proof-of-concept study provides compelling evidences that ZY-1-based probes are a promising tool for the early diagnosis and staging of liver fibrosis and paves the way for further development of clinical-related diagnosis strategies for fibrotic diseases of the liver and other organs. Statement of significance Currently, early diagnosis and accurate staging of liver fibrosis continue to present significant challenges. This study demonstrates that fluorescent probes based on the nucleic acid aptamer ZY-1, which targets cellular fibronectin (cFN)—a crucial extracellular matrix (ECM) molecule that significantly accumulates during liver fibrosis—are promising bioimaging agents for staging liver fibrosis. The ZY-1-based fluorescent probes effectively identified and differentiated early-stage liver fibrosis from advanced liver fibrosis. This proof-of-concept study not only provides compelling evidence that ZY-1-based probes show promise for the early diagnosis and staging of liver fibrosis but also paves the way for further investigations into the use of ZY-1 in detecting other diseases associated with cFN.

Identification of early-stage liver fibrosis by modifications in the interstitial space diffusive microenvironment using fluorescent single-walled carbon nanotubes

Identification of Early Stage Liver Fibrosis by Modifications in the Interstitial Space Diffusive Microenvironment Using Fluorescent Single-Walled Carbon Nanotubes

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Novel Strategy for Validating the Existence and Mechanism of the "gut-liver axis" in Vivo by a Hypoxia-Sensitive NIR Fluorescent Probe.

Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis

Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles

Dynamic Changes of Key Metabolites During Liver Fibrosis in Rats.

Diffusion Tensor Imaging of Liver Fibrosis in an Experimental Model

SERS diagnosis of liver fibrosis in the early stage based on gold nanostar liver targeting tags

Transcriptional regulatory mechanisms of fibrosis development in mouse lung tissue exposed to carbon nanotubes

Recent Advances of Nanomaterials in Imaging Liver Fibrosis

Hepatic Stellate Cell-Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis

A novel alternative strategy for monitoring and insight into liver fibrosis progression: The combination of surface-enhanced Raman spectroscopy (SERS) and gut microbiota

Point‐of‐care detection of fibrosis in liver transplant surgery using near‐infrared spectroscopy and machine learning

Mechanotransduction-modulated Fibrotic Microniches Reveal the Contribution of Angiogenesis in Liver Fibrosis

Enhanced US/CT/MR imaging of integrin αvβ3 for liver fibrosis staging in rat

Nonlinear Optical Microscopy: Use of Second Harmonic Generation and Two-Photon Microscopy for Automated Quantitative Liver Fibrosis Studies

Molecular MRI of Liver Fibrosis by a Peptide-Targeted Contrast Agent in an Experimental Mouse Model

Label-free characterization of pathological changes in the portal area of liver fibrosis tissue using multiphoton imaging and quantitative image analysis

The role of sinusoidal endothelial cells and TIMP1 in the regulation of fibrosis in a novel human liver 3D NASH model

Exploring the impact of severity in hepatic fibrosis disease on the intrahepatic distribution of novel biodegradable nanoparticles targeted towards different disease biomarkers